JP2022513438A5 - - Google Patents

Info

Publication number
JP2022513438A5
JP2022513438A5 JP2021531557A JP2021531557A JP2022513438A5 JP 2022513438 A5 JP2022513438 A5 JP 2022513438A5 JP 2021531557 A JP2021531557 A JP 2021531557A JP 2021531557 A JP2021531557 A JP 2021531557A JP 2022513438 A5 JP2022513438 A5 JP 2022513438A5
Authority
JP
Japan
Application number
JP2021531557A
Other languages
Japanese (ja)
Other versions
JP7483234B2 (ja
JP2022513438A (ja
JPWO2020117590A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063619 external-priority patent/WO2020117590A1/en
Publication of JP2022513438A publication Critical patent/JP2022513438A/ja
Publication of JPWO2020117590A5 publication Critical patent/JPWO2020117590A5/ja
Publication of JP2022513438A5 publication Critical patent/JP2022513438A5/ja
Priority to JP2024068841A priority Critical patent/JP2024099671A/ja
Application granted granted Critical
Publication of JP7483234B2 publication Critical patent/JP7483234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531557A 2018-12-04 2019-11-27 Hivワクチン免疫原 Active JP7483234B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024068841A JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862775192P 2018-12-04 2018-12-04
US62/775,192 2018-12-04
PCT/US2019/063619 WO2020117590A1 (en) 2018-12-04 2019-11-27 Hiv vaccine immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024068841A Division JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Publications (4)

Publication Number Publication Date
JP2022513438A JP2022513438A (ja) 2022-02-08
JPWO2020117590A5 JPWO2020117590A5 (https=) 2022-11-18
JP2022513438A5 true JP2022513438A5 (https=) 2022-11-18
JP7483234B2 JP7483234B2 (ja) 2024-05-15

Family

ID=70974318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531557A Active JP7483234B2 (ja) 2018-12-04 2019-11-27 Hivワクチン免疫原
JP2024068841A Pending JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024068841A Pending JP2024099671A (ja) 2018-12-04 2024-04-22 Hivワクチン免疫原

Country Status (10)

Country Link
US (2) US12239698B2 (https=)
EP (2) EP3891170B1 (https=)
JP (2) JP7483234B2 (https=)
KR (1) KR20210124205A (https=)
CN (2) CN113454100B (https=)
AU (2) AU2019393745B2 (https=)
CA (1) CA3120324A1 (https=)
ES (1) ES2993834T3 (https=)
PL (1) PL3891170T3 (https=)
WO (1) WO2020117590A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114732898B (zh) * 2022-04-01 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种CpG佐剂与抗原定点共价结合方法
WO2024130122A2 (en) * 2022-12-15 2024-06-20 The Wistar Institute Of Anatomy And Biology Hiv immunogens and methods of using same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
WO1993001831A1 (en) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
AU2002336417A1 (en) 2001-08-31 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Methods of generating human cd4+ th1 cells
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2765138B1 (en) * 2012-11-05 2018-01-10 International Aids Vaccine Initiative HIV-1 envelope glycoprotein
WO2015134982A1 (en) * 2014-03-07 2015-09-11 Cornell University Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers
ES2789348T3 (es) * 2015-03-20 2020-10-26 Us Health Anticuerpos neutralizantes para GP120 y sus usos
WO2016196975A1 (en) 2015-06-03 2016-12-08 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2017055522A1 (en) * 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
WO2018161049A1 (en) 2017-03-03 2018-09-07 Duke University Compositions and methods for inducing hiv-1 antibodies
WO2017165674A1 (en) * 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
US20210009640A1 (en) * 2018-03-02 2021-01-14 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021017173A2 (https=)